LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
Provided By GlobeNewswire
Last update: Feb 25, 2025
-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100
in Combination with GSK’s Immunotherapy Dostarlimab --
0.1508
-0.07 (-31.49%)
4.11
-0.18 (-4.2%)
Find more stocks in the Stock Screener
